title: Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
abstract: BACKGROUND
  Treatment of osteoporotic women with PTH increases biochemical markers of bone turnover, increases axial bone mineral density (BMD), and reduces fracture risk.
  
  
  OBJECTIVE
  Our objective was to determine the relationship between levels of baseline turnover before PTH therapy and short-term changes in turnover during PTH therapy and subsequent changes in areal and volumetric BMD.
  
  
  METHODS
  We conducted a randomized, placebo-controlled trial at four academic centers.
  
  
  METHODS
  Patients included 238 postmenopausal women with low hip or spine BMD.
  
  
  METHODS
  Subjects were randomized to sc PTH (1-84), 100 mug/d (119 women), for 1 yr.
  
  
  METHODS
  Bone turnover markers were measured in fasting blood samples collected before therapy and after 1 and 3 months. Areal and volumetric BMD at the spine and hip were assessed by dual-energy x-ray absorptiometry and quantitative computed tomography (QCT) after 1 yr of therapy.
  
  
  RESULTS
  Among women treated with PTH alone, the relationships between baseline turnover and 1-yr changes in dual-energy x-ray absorptiometry and QCT BMD were inconsistent. Greater 1- and 3-month increases in turnover, particularly the formation marker N-propeptide of type I collagen, were associated with greater increases in areal BMD. When volumetric hip and spine BMD were assessed by QCT, greater short-term increases in turnover were even more positively associated with 1-yr increases in BMD. Each sd increase in the 3-month change of N-propeptide of type I collagen was associated with an a 21% greater increase in QCT spine trabecular BMD.
  
  
  CONCLUSIONS
  Greater short-term changes in turnover with PTH therapy are associated with greater 1-yr increases in spine and hip BMD among postmenopausal osteoporotic women.
authors.affiliation: Department of Medicine, University of California-San Francisco Coordinating Center, 185 Berry 5700, San Francisco, CA 94107, USA. DBauer@psg.ucsf.edu
authors.forename: D C
authors.initials: DC
authors.lastname: Bauer
authors.forename: P
authors.initials: P
authors.lastname: Garnero
authors.forename: J P
authors.initials: JP
authors.lastname: Bilezikian
authors.forename: S L
authors.initials: SL
authors.lastname: Greenspan
authors.forename: K E
authors.initials: KE
authors.lastname: Ensrud
authors.forename: C J
authors.initials: CJ
authors.lastname: Rosen
authors.forename: L
authors.initials: L
authors.lastname: Palermo
authors.forename: D M
authors.initials: DM
authors.lastname: Black
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000627:therapeutic use; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism*; D010281:Parathyroid Hormone / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D019386:Alendronate